Ireland's logistical standing in global pharmaceuticals is built on manufacturing excellence, but sustaining it increasingly depends on cold chain capability. Medical and pharmaceutical products accounted for 45 per cent of Ireland's goods exports in 2024, reaching €99.9 billion according to the Central Statistics Office, and nine of the world's top ten pharmaceutical companies operate on the island. The Pharmaceutical Commerce cold chain review, published in March 2026 and authored by Editor Emeritus Nick Basta, sets out why Irish logistics operators have a compelling opportunity to build world-class capability.

The review argues the global pharma cold chain is entering sustained growth, driven by biologics, cell and gene therapies, and temperature-sensitive blockbuster medicines. For Ireland, operators investing proactively will be better placed to serve manufacturers, attract new contracts, and strengthen the country's position as a life sciences hub. Three developments are most relevant: cell and gene therapies as a new logistical frontier, digital monitoring and IoT visibility, and capital investment by global 3PL providers.

Cell and gene therapies represent the most demanding evolution in pharmaceutical logistics, requiring traceable, closed-loop logistics and cryogenic preservation at temperatures as low as minus 80 degrees Celsius. The review notes the global pharma cold chain market stands at between $9.2 billion (€7.8 billion) and $27.6 billion (€23.6 billion) annually, with healthcare logistics overall valued at $60 billion (€51.3 billion). Building certified cryogenic capacity is a natural extension of competencies for Irish operators servicing biopharma manufacturers.

Digital monitoring is transforming cold chain management from a compliance function into a competitive differentiator. The review highlights how IoT devices, dataloggers, and cloud automation deliver end-to-end visibility, proof-of-delivery documentation, and predictive excursion management. In Europe, the pharmaceutical cold chain market was valued at $21.5 billion (€18.4 billion) in 2025 and is projected to reach $28.3 billion (€24.2 billion) by 2031 according to Mordor Intelligence, with EU Good Distribution Practice mandates making real-time data integrity a regulatory requirement.

Major global 3PL providers are reinforcing the opportunity with substantial capital. The review documents multibillion-dollar programmes by DHL, Kuehne and Nagel, and UPS across healthcare air routes, cryogenic warehousing, and last-mile distribution. The global healthcare cold chain 3PL market, valued at $45.8 billion (€39.2 billion) in 2025, is projected to reach $83.4 billion (€71.4 billion) by 2033 according to Grand View Research. Alignment with these networks gives Irish operators access to technology and expertise that would take years to build.

Three specific actions merit prioritisation. Operators should invest in Good Distribution Practice certification and validated cryogenic storage, positioning as preferred partners for cell and gene therapy manufacturers. Organisations should deploy IoT-enabled temperature monitoring, building the data infrastructure pharmaceutical clients and EU regulators require. Boards should pursue partnerships with global 3PL providers offering a path to scale.

Ireland's pharmaceutical sector has consistently rewarded operators matching its ambitions. The Pharmaceutical Commerce review confirms demand expanding, technology maturing, and the regulatory framework strengthening in ways that favour operators who invest with conviction. For Irish logistics leaders, cold chain investment is investment in Ireland's most valuable export sector.

(The views expressed by the writer are his/her own and do not necessarily reflect the views or positions of BusinessRiver.)